Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Basilea Pharmaceutica's change in inventory for the quarter that ended in Dec. 2025 was CHF1.1 Mil. It means Basilea Pharmaceutica's inventory
declined by CHF1.1 Mil
from Jun. 2025 to Dec. 2025 .
Basilea Pharmaceutica's change in inventory for the fiscal year that ended in Dec. 2025 was CHF10.1 Mil. It means Basilea Pharmaceutica's inventory
declined by CHF10.1 Mil
from Dec. 2024 to Dec. 2025 .
Days Inventory indicates the number of days of goods in sales that a company has in the inventory.
Basilea Pharmaceutica's Days Inventory for the quarter that ended in Dec. 2025 was 267.12.
Inventory Turnover measures how fast the company turns over its inventory within a year.
Basilea Pharmaceutica's Inventory Turnover for the quarter that ended in Dec. 2025 was 0.68.
Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.
Basilea Pharmaceutica's Inventory-to-Revenue for the quarter that ended in Dec. 2025 was 0.17.
Basilea Pharmaceutica (XSWX:BSLN) Change In Inventory Explanation
1. Days Inventory indicates the number of days of goods in sales that a company has in the inventory.
Basilea Pharmaceutica's Days Inventory for the quarter that ended in is calculated as:
3. Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.
Basilea Pharmaceutica's Inventory to Revenue for the quarter that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Basilea Pharmaceutica Change In Inventory Related Terms
Basilea Pharmaceutica Change In Inventory Historical Data
* Premium members only.
The historical data trend for Basilea Pharmaceutica's Change In Inventory can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Basilea Pharmaceutica Change In Inventory Calculation
Change In Inventory is the difference between last period's ending inventory and the current period's ending inventory.
Change In Inventory for the trailing twelve months (TTM) ended in Dec. 2025 adds up the semi-annually data reported by the company within the most recent 12 months, which was CHF10.1 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a Change In Inventory of CHF10.1 Mil mean?
Basilea Pharmaceutica (XSWX:BSLN) has a Change In Inventory of CHF10.1 Mil as of Dec. 2025. Change in Inventory is the difference between current-period inventory and past-period inventory. View historical data for Basilea Pharmaceutica and its competitors.
Is Basilea Pharmaceutica's Change In Inventory too high?
Basilea Pharmaceutica's current Change In Inventory is CHF10.1 Mil. Overall, Basilea Pharmaceutica has a GF Score™ of 58/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Basilea Pharmaceutica's Change In Inventory compare to VRTX and REGN?
Basilea Pharmaceutica's Change In Inventory of CHF10.1 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Change In Inventory for a Biotechnology company?
A good Change In Inventory depends on the Biotechnology industry context. However, Change In Inventory should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Change In Inventory mean?
A high Change In Inventory can signal that a stock is expensive relative to its fundamentals. Change in Inventory is the difference between current-period inventory and past-period inventory. View historical data for Basilea Pharmaceutica and its competitors. Basilea Pharmaceutica's current Change In Inventory is CHF10.1 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Basilea Pharmaceutica stock overvalued right now?
Based on GuruFocus' analysis, Basilea Pharmaceutica (XSWX:BSLN) is currently considered Fairly Valued. The stock's GF Value™ is CHF57.90, compared to a current price of CHF52.60 — trading 9.2% below its estimated fair value. The current Change In Inventory is CHF10.1 Mil. Basilea Pharmaceutica's overall GF Score™ is 58/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Change In Inventory calculated?
Change In Inventory is calculated from a company's financial statements. For Basilea Pharmaceutica (XSWX:BSLN), the current Change In Inventory is CHF10.1 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Basilea Pharmaceutica (XSWX:BSLN) Overvalued in 2026?
Based on GuruFocus' analysis, Basilea Pharmaceutica stock appears to be undervalued.
The current stock price of CHF52.60 is trading 9.2% below its estimated GF Value™ of CHF57.90.
GuruFocus considers Basilea Pharmaceutica to be Fairly Valued.
Key valuation signals for XSWX:BSLN:
Change In Inventory: CHF10.1 Mil
GF Value™: CHF57.90 vs. price of CHF52.60 (9.2% below fair value)
No single metric tells the full story. See the XSWX:BSLN stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Basilea Pharmaceutica Ltd is a commercial-stage biopharmaceutical company committed to discovering, developing and commercializing drugs to meet the needs of patients with severe bacterial and fungal infections. The Company has operating subsidiaries in the United Kingdom and Germany. Geographically company derives revenue from Japan, Ireland, Republic of Korea, USA, Uruguay, Sweden, Canada, Jordan, Switzerland and Other countries.
58GF Score
Get the complete analysis for XSWX:BSLN
Change In Inventory is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XSWX:BSLN has been successfully added to your 
